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DOI 10.1002/ajmg.a.37009Patients with biallelic mutations for Huntington disease (HD)
are rare. We present a 46-year-old female with two expanded
Huntingtin (HTT) alleles with just one known affected parent.
This is the first reported patient with molecular studies per-
formed to excludeHTTuniparental disomy (UPD). The proband
had biparental inheritance of HTT alleles (42/44 CAG repeats).
Given the negative UPD results, the proband’s unaffected moth-
er either had a reduced penetrance allele that expanded into the
full mutation range during transmission to our patient or an
unknown full HTT mutation and died before symptom onset,
unlikely given no family history of HD and asymptomatic at age
59. We made the novel observation in our literature review
that most patients with biallelic HD did not have two full
HTT mutations. Most had one HTT allele that was in the
intermediate or reduced penetrance ranges or 40 CAG repeats,
the lowest limit of the full mutation range. Although the number
of patients is small, when an allele in these size ranges was
present, generally the age of HD onset was in the 50s. If the
secondHTT allele had>45 repeats, then onset was typically 20s–
30s. While similar ages of onset have been reported for patients
withoneor twoHTTmutations, patientswithbiallelicmutations
may have later onset if an expanded HTT allele has 40 CAG
repeats. Finally, we propose that “biallelic mutations” or “com-
pound heterozygosity” are more accurate descriptive terms than
“homozygosity” when there are two non-identical expanded
HTT alleles.  2015 Wiley Periodicals, Inc.
Key words: Huntington disease (HD); biallelic mutations;
biallelic Huntington disease; compound heterozygote; compound
heterozygosity; homozygotes; homozygosity; reduced penetrance
alleles; intermediate alleles; uniparental disomy (UPD)2015 Wiley Periodicals, Inc.INTRODUCTION
Huntington disease (HD) is an autosomal dominantly inherited
neurological condition with progressive cognitive, motor, and
psychiatric symptoms. The mean age of onset is 35–44 years
[Warby et al., 1998]. Huntington disease is caused by a CAG
trinucleotide repeat expansion in the HTT gene on chromosome
4 with repeat numbers defined as: full mutation (40 or more),
reduced penetrance (36–39), intermediate (27–35) and normal
(26 or less) [ACMG/ASHG Huntington Disease Genetic Testing
Working Group 1998; Potter et al., 2004]. Intermediate and1152
UHLMANN ET AL. 1153reduced penetrance alleles are unstable and can expand into the full
mutation range when transmitted, primarily in paternal trans-
missions [Goldberg et al., 1993, 1995; Maat-Kievit et al., 2001a;
Semaka et al., 2006, 2010, 2013a; Brocklebank et al., 2009; Sequeiros
et al., 2010; Aziz et al., 2011; Semaka and Hayden, 2014].
The prevalence of HD is estimated to be 12–15/100,000 in
individuals of European descent [Warby et al., 1998; Evans et al.,
2013; Fisher and Hayden, 2014]. Patients with biallelic CAG
expansion alleles have previously been described as “homozygous”,
but we suggest that the terms “biallelic” or “compound heterozy-
gous” would bemore accurate. Biallelic HDhas occurred in diverse
ethnic groups (Table I) and the prevalence in two large family
studies of affected individuals ranged from 0.1%, N¼ 1007
[Kremer et al., 1994] to 0.4%,N¼ 263 [Alonso et al., 2002]. Studies
of patients with biallelic HD have generally reported similar fea-
tures, age of onset, and disease course as heterozygous individuals
[Young et al., 1986; Wexler et al., 1987; Myers et al., 1989; Kremer
et al., 1994;Durr et al., 1999; Laccone et al., 1999;Alonso et al., 2002;
Costa et al., 2003]. One study [Squitieri et al., 2003a] suggested that
the clinical course is more severe and progression more rapid in
patients with biallelic HD.
In the absence of a second known affected parent and after
excluding technical artifacts or limitations (e.g., primer issues,
somatic mosaicism, very long repeats requiring Southern blotting
for identification), possible explanations for biallelic HD include:
(1)non-paternity (non-maternity is implausible except in IVF cases
with egg donation or a father and present partner raising a child
from an undisclosed previous relationship) (2) an intermediate or
reduced penetrance HTT allele in the unaffected parent (3) a full
mutation allele in anasymptomatic parentwhodiedprematurely or
has not lived long enough to develop symptoms (unlikely if no
family history of HD) or (4) HTT uniparental isodisomy.
Uniparental disomy (UPD) occurs in a number of genetic
conditions [Engel, 2006; Kotzot, 2008; Yamazawa et al., 2010].
Maternal UPD for chromosome 4 has been reported [Kuchinka
et al., 2001; Spena et al., 2004; Middleton et al., 2006; Cottrell et al.,
2012; Ding et al., 2012] and there is one published paternal
segmental UPD(4) clinical report [Elli et al., 2012]. No reports
of UPD for HD were identified in our literature review.
We present a 46-year-old female with biallelic HTT mutations
with one affected parent (father), in whom we performed UPD
testing to rule out the possibility that she inherited two paternal
HTT alleles. We also reviewed the literature and summarize the
genetic test results and ages of onset reported to date in individuals
with biallelic HD.MATERIALS AND METHODS
This study was approved by the University of Michigan Medical
School Institutional Review Board, which operates under 45 CFR
46. Both the subject of this report and her husband provided
informed consent.Clinical Report
The 46-year-old female patient was evaluated by a neurologist
(RLA) because of a 1–2 year history of progressive incoordinationand declining memory. She had a history of recurrent
depression requiring medical treatment. The patient reported
increasing difficulty with performing her manual labor job.
Family members noted involuntary limb movements. Saccadic
eye movements were slowed with involuntary head turning and
involuntary blinking during saccade initiation. There was a mild
intermittent rotatory head tremor. Rapid finger movements
were moderately slowed, tone and casual gait were normal,
with mildly impaired tandem gait. Choreoathetosis was noted
in fingers and toes.
Limited family history information (Fig. 1) and medical
records were available. The patient’s father was cared for by
RLA and had HD, confirmed by autopsy, with onset in his
early 50s and deceased at age 68. The patient had a brother
and a sister. Her brother, also followed by RLA, developed HD
in his late 20s and died at age 43; no genetic testing or autopsy was
performed. By family report, her asymptomatic 37-year-old sister
had positive presymptomatic genetic test results for HD. The
children of the patient’s siblings, two daughters and a son,
were reported to be asymptomatic. The patient’s mother died
at age 59 of a cerebral aneurysm and was not reported to have a
family history of HD or any other neurologic conditions. There
was no parental consanguinity. The patient was diagnosed with
manifest HD at age 46.CAG Repeat Size Analysis and Uniparental
Disomy Studies
A blood sample was obtained from the patient and DNA was
isolated. The HTT gene was amplified in three separate reactions
using the polymerase chain reaction (PCR) followed by capillary
electrophoresis of the fluorescent PCR products to determine the
CAG triplet repeat lengths. The three reactions amplify the CAGn
þCCGn region, the CCGn region alone and theCAGn region alone.
These tests may not detect expansions of greater than 80 trinucleo-
tide repeats. A Coriell cell line (NA13510) with 15 and 44 CAG
repeats was used as a positive control (sequencing confirmed CAG
repeat numbers).
Molecular polymorphism studies were performed to rule out the
possibility that the patient had inherited two copies of the paternal
HTT allele as a result of UPD. The patient’smother was deceased so
no maternal DNA was available. DNA was isolated from the
patient’s blood sample and her deceased affected father’s brain
tissue. Markers used (Supplemental Online Table SI) included
microsatellites flanking the HTT gene [primer information and
mapping data is available for all microsatellites through the
National Center for Biotechnology Information (NCBI)]. Markers
were genotyped by PCR using fluorescently labeled primers, with
PCR products quantified on an ABI 310 Prism Genetic Analyzer
(ABI, Foster City, CA).RESULTS
The result from the first reaction amplifying the CAGnþCCGn
region was 43 and 45 repeats. The result from the second reaction
amplifying the CCGn region alone was seven repeats. Amplifying
TA
B
LE
I.
St
ud
ie
s
th
at
R
ep
or
te
d
In
di
vi
du
al
s
w
it
h
B
ia
lle
lic
H
un
ti
n
gt
on
D
is
ea
se
1
St
ud
y/
ye
ar
(l
oc
at
io
n
)
N
um
be
r
of
pa
ti
en
ts
w
it
h
bi
al
le
lic
H
D
1
Pa
re
n
ts
’
st
at
us
Pa
re
n
ts
re
la
te
d?
CA
G
re
pe
at
n
um
be
rs
(a
lle
le
1
/a
lle
le
2
)
St
at
us
/a
ge
(y
ea
rs
)
of
on
se
t
or
ag
e
at
ti
m
e
of
st
ud
y
if
as
ym
pt
om
at
ic
(A
)
G
en
de
r
(n
um
be
r)
Yo
un
g
et
al
.
[1
9
8
6
]
1
8
(p
os
si
bl
e)
B
ot
h
af
fe
ct
ed
N
ot
pr
ov
id
ed
bu
t
al
lf
ro
m
N
eu
ro
lo
gi
c
ex
am
in
at
io
n
3
-a
du
lt
-o
n
se
t
F
(1
1
)
(M
ar
ac
ai
bo
,
Ve
n
ez
ue
la
)
is
ol
at
ed
co
m
m
un
it
y
on
ly
2
-ju
ve
n
ile
-o
n
se
t
M
(7
)
8
-s
of
t
si
gn
s
5
-,
–
W
ex
le
r
et
al
.
[1
9
8
7
]
4
(i
n
sa
m
e
B
ot
h
af
fe
ct
ed
Fi
rs
t
co
us
in
s
on
ce
Li
n
ka
ge
1
-D
ef
in
it
iv
e
H
D
–
(M
ar
ac
ai
bo
,
Ve
n
ez
ue
la
)
si
bs
hi
p)
2
re
m
ov
ed
.3
1
-S
of
t
si
gn
s
–
1
-N
eu
ro
lo
gi
ca
lly
n
or
m
al
–
1
-,
–
–
M
ye
rs
et
al
.
[1
9
8
9
]
(N
ew
4
(p
os
si
b
le
,
in
B
ot
h
af
fe
ct
ed
Fi
rs
t
co
us
in
s
(t
w
o
Li
n
ka
ge
3
4
–
En
gl
an
d,
U
SA
)
th
re
e
si
bs
hi
ps
)
m
at
in
gs
),
se
co
n
d
4
6
–
co
us
in
s
(o
n
e
m
at
in
g)
.
5
8
–
7
4
(A
)
–
H
un
ti
n
gt
on
’s
D
is
ea
se
Co
lla
bo
ra
ti
ve
R
es
ea
rc
h
G
ro
up
[1
9
9
3
]
5
in
sa
m
e
Ve
n
ez
ue
la
n
si
bs
hi
p
4
;
B
ot
h
af
fe
ct
ed
R
el
at
ed
by
m
ar
ke
r
st
ud
ie
s
Fi
rs
t
CA
G
an
al
ys
is
re
po
rt
;
sp
ec
ifi
c
re
pe
at
n
um
be
rs
n
ot
pr
ov
id
ed
“a
ge
of
on
se
t
ap
pe
ar
s
to
pa
ra
lle
l
re
pe
at
le
n
gt
h”
6
–
(M
ar
ac
ai
bo
,
Ve
n
ez
ue
la
an
d
U
SA
)
1
-A
m
er
ic
an
fa
m
ily
–
Li
ke
ly
re
la
te
d
5
–
K
re
m
er
et
al
.
[1
9
9
4
]
(W
or
ld
w
id
e
st
ud
y)
7
2
1
-
M
ot
he
r
af
fe
ct
ed
,
fa
th
er
un
af
fe
ct
ed
(d
ie
d
in
4
0
s)
–
3
7
/4
3
5
0
F
2
-
Fa
th
er
af
fe
ct
ed
,
m
ot
he
r
un
af
fe
ct
ed
an
d
n
eg
at
iv
e
fa
m
ily
hi
st
or
y8
–
3
9
/4
2
2
5
(A
)
F
Sa
n
ch
ez
et
al
.
[1
9
9
6
]
(S
p
ai
n
)
1
M
ot
he
r
af
fe
ct
ed
;
fa
th
er
cl
in
ic
al
ly
n
or
m
al
N
ot
kn
ow
n
to
be
re
la
te
d
bu
t
bo
th
fr
om
sa
m
e
vi
lla
ge
of
7
0
0
in
ha
bi
ta
n
ts
4
0
/5
3
5
4
F
D
ur
r
et
al
.
[1
9
9
9
]
(F
ra
n
ce
)
1
B
ot
h
af
fe
ct
ed
Fi
rs
t
co
us
in
s
4
2
/4
6
3
3
M
La
cc
on
e
et
al
.
[1
9
9
9
]
2
3
–
–
3
9
/6
2
2
2
–
(M
ul
ti
ce
n
te
r
st
ud
y
in
3
9
/4
3
5
5
–
Au
st
ri
a,
G
er
m
an
y,
Sw
it
ze
rl
an
d
)
2
1
w
it
h
al
le
le
>
3
9
ha
d
2
n
d
al
le
le
3
1
–
3
9
re
pe
at
s
–
–
1154 AMERICAN JOURNAL OF MEDICAL GENETICS PART A
TA
B
LE
I.
(C
on
ti
nu
ed
)
St
u
dy
/y
ea
r
(l
oc
at
io
n
)
N
um
be
r
of
pa
ti
en
ts
w
it
h
bi
al
le
lic
H
D
1
Pa
re
n
ts
’
st
at
us
Pa
re
n
ts
re
la
te
d?
CA
G
re
pe
at
n
um
be
rs
(a
lle
le
1
/a
lle
le
2
)
St
at
us
/a
ge
(y
ea
rs
)
of
on
se
t
or
ag
e
at
ti
m
e
of
st
ud
y
if
as
ym
pt
om
at
ic
(A
)
G
en
de
r
(n
um
be
r)
M
aa
t-
K
ie
vi
t
et
al
.
[2
0
0
1
a]
3
(i
n
sa
m
e
Fa
th
er
af
fe
ct
ed
,
m
ot
he
r
–
3
6
/4
6
A
(h
ad
ch
ild
re
n
)
F
(T
he
N
et
he
rl
an
ds
)
si
b
sh
ip
)
su
sp
ec
te
d
af
fe
ct
ed
3
6
/4
6
A
(r
ep
ro
du
ct
iv
e
ag
e)
F
3
6
/4
5
A
(h
ad
ch
ild
re
n
)
M
Al
on
so
et
al
.
[2
0
0
2
]
(M
ex
ic
o)
1
B
ot
h
su
sp
ec
te
d
af
fe
ct
ed
N
ot
kn
ow
n
to
be
re
la
te
d
bu
t
bo
th
fr
om
sa
m
e
to
w
n
w
it
h
<
1
,0
0
0
in
ha
bi
ta
n
ts
3
9
/4
1
5
2
–
Co
st
a
et
al
.
[2
0
0
3
]
6
1
-
m
ot
he
r
af
fe
ct
ed
–
3
9
/5
1
3
1
M
(P
or
tu
ga
l)
2
-
m
ot
he
r
af
fe
ct
ed
–
3
6
/4
7
2
4
(A
)
F
3
-
m
ot
he
r
af
fe
ct
ed
–
3
2
/4
3
5
1
F
4
-
fa
th
er
af
fe
ct
ed
–
3
2
/4
2
5
0
F
5
-
fa
th
er
af
fe
ct
ed
–
2
9
/5
2
3
2
M
6
-
m
ot
he
r
af
fe
ct
ed
–
2
8
/4
9
2
8
F
Sq
ui
ti
er
i
et
al
.
[2
0
0
3
a]
8
1
-m
ot
he
r
af
fe
ct
ed
–
4
2
/4
4
5
7
M
(M
ul
ti
ce
n
te
r
st
ud
y
in
2
-b
ot
h
af
fe
ct
ed
–
4
0
/4
6
5
7
F
Au
st
ra
lia
,C
an
ad
a,
Fr
an
ce
,
It
al
y,
Sc
ot
la
n
d)
3
-m
ot
he
r
af
fe
ct
ed
–
4
0
/4
4
4
9
M
4
-,
–
–
4
0
/4
1
5
8
F
5
-m
ot
he
r
af
fe
ct
ed
–
3
9
/4
3
4
0
F
6
-b
ot
h
su
sp
ec
te
d
af
fe
ct
ed
–
3
7
/4
0
6
0
M
7
-m
ot
he
r
su
sp
ec
te
d
–
3
6
/4
4
5
1
F
8
-,
–
–
3
6
/3
7
4
5
M
W
ex
le
r
et
al
.
[2
0
0
4
]/
Th
e
U
.S
.-V
en
ez
ue
la
Co
lla
bo
ra
ti
ve
R
es
ea
rc
h
Pr
oj
ec
t
(M
ar
ac
ai
b
o,
Ve
n
ez
ue
la
)
1
8
9
N
ot
pr
ov
id
ed
bu
t
in
ea
rl
ie
r
st
ud
ie
s
bo
th
pa
re
n
ts
w
er
e
re
po
rt
ed
af
fe
ct
ed
N
ot
pr
ov
id
ed
bu
t
al
lf
ro
m
is
ol
at
ed
co
m
m
un
it
y.
In
ea
rl
ie
r
st
ud
ie
s,
co
n
sa
n
gu
in
it
y
re
po
rt
ed
in
so
m
e
1
5
-b
ot
h
al
le
le
s

4
0
1
2
/1
5
ha
d
m
ea
n
ag
e
of
on
se
t
2
8
.7
5

6
.1
7
1
0
3
/1
5
,
–
– –
ca
se
s.
3
-1
al
le
le

4
0
an
d
2
n
d
al
le
le
3
5
–
3
9
3
/3
ha
d
m
ea
n
ag
e
of
on
se
t
3
5
.3
3

7
.2
3
1
0
–
Le
e
et
al
.[
2
0
1
2
]
(H
D
-M
AP
S,
1
0
–
–
4
2
/4
2
–
–
CO
H
O
R
T,
PR
ED
IC
T-
H
D
,
R
EG
IS
TR
Y,
M
as
sa
ch
us
et
ts
,
U
SA
)
8
–
1
al
le
le
3
5
–
3
9
1
1
4
ha
d
on
se
t
5
0
sþ
1
1
–
Sh
i
et
al
.
[2
0
1
2
]
(C
h
in
a
–
H
an
et
hn
ic
gr
ou
p)
1
M
ot
he
r
af
fe
ct
ed
(4
2
/2
0
).
Fa
th
er
un
af
fe
ct
ed
at
ag
e
6
6
(3
7
/1
7
)
N
ot
kn
ow
n
to
be
re
la
te
d
3
7
/4
2
3
8
(A
)
–
UHLMANN ET AL. 1155
TA
B
LE
I.
(C
on
ti
nu
ed
)
St
u
dy
/y
ea
r
(l
oc
at
io
n
)
N
um
be
r
of
pa
ti
en
ts
w
it
h
bi
al
le
lic
H
D
1
Pa
re
n
ts
’
st
at
us
Pa
re
n
ts
re
la
te
d?
CA
G
re
pe
at
n
um
be
rs
(a
lle
le
1
/a
lle
le
2
)
St
at
us
/a
ge
(y
ea
rs
)
of
on
se
t
or
ag
e
at
ti
m
e
of
st
ud
y
if
as
ym
pt
om
at
ic
(A
)
G
en
de
r
(n
um
be
r)
U
hl
m
an
n
et
al
.
(M
ic
hi
ga
n
,
U
SA
)
1
Fa
th
er
af
fe
ct
ed
(2
1
/4
2
).
M
ot
he
r
un
af
fe
ct
ed
(d
ie
d
at
5
9
)
an
d
ha
d
n
eg
at
iv
e
fa
m
ily
hi
st
or
y
N
ot
kn
ow
n
to
be
re
la
te
d
4
2
/4
4
1
2
4
4
F
Th
e
st
ud
ie
s
ar
e
pr
es
en
te
d
by
pu
bl
ic
at
io
n
da
te
to
pr
ov
id
e
a
hi
st
or
ic
pe
rs
pe
ct
iv
e.
G
iv
en
th
at
se
ve
ra
ls
tu
di
es
w
er
e
on
in
di
vi
du
al
s
fr
om
M
ar
ac
ai
bo
,V
en
ez
ue
la
,s
om
e
of
th
e
sa
m
e
pa
ti
en
ts
m
ay
ap
pe
ar
in
m
ul
ti
pl
e
st
ud
ie
s.
In
so
m
e
st
ud
ie
s,
n
eu
ro
lo
gi
ca
ls
ta
tu
s
w
as
n
ot
pr
ov
id
ed
ei
th
er
to
pr
es
er
ve
pa
ti
en
tc
on
fi
de
n
ti
al
it
y,
th
e
ob
je
ct
iv
it
y
of
re
se
ar
ch
er
s,
or
be
ca
us
e
pa
rt
ic
ip
an
ts
w
er
e
to
o
yo
un
g
fo
rs
ym
pt
om
on
se
t.
CA
G
re
pe
at
ra
n
ge
s:
N
or
m
al
(
2
6
),
In
te
rm
ed
ia
te
(2
7
–
3
5
),
R
ed
uc
ed
Pe
n
et
ra
n
ce
(3
6
–
3
9
),
H
un
ti
n
gt
on
D
is
ea
se
(>
3
9
)
F-
Fe
m
al
e,
M
-
m
al
e;
A-
as
ym
pt
om
at
ic
;
–
,
n
ot
pr
ov
id
ed
.
1
In
th
e
lit
er
at
ur
e,
th
es
e
st
ud
ie
s
us
e
th
e
te
rm
s
“h
om
oz
yg
ot
es
,”
“h
om
oz
yg
ou
s”
an
d
“h
om
oz
yg
os
it
y”
fo
r
H
un
ti
n
gt
on
di
se
as
e.
2
Li
ke
ly
th
es
e
in
di
vi
du
al
s
w
er
e
in
cl
ud
ed
in
Yo
un
g
et
al
.
[1
9
8
6
]
st
ud
y.
3
Fi
gu
re
te
xt
st
at
es
pa
re
n
ts
of
ho
m
oz
yg
ot
es
ar
e
se
co
n
d
co
us
in
s
on
ce
re
m
ov
ed
bu
t
pe
di
gr
ee
sh
ow
s
th
ey
ar
e
1
st
co
us
in
s
on
ce
re
m
ov
ed
(F
ig
ur
e
1
,
p.
1
9
5
).
4
Sa
m
e
ho
m
oz
yg
ot
es
re
po
rt
ed
by
W
ex
le
r
et
al
.
[1
9
8
7
].
5
Fi
gu
re
le
ge
n
d
st
at
es
in
di
vi
du
al
ho
m
oz
yg
ou
s
fo
r
th
e
sa
m
e
H
D
ch
ro
m
os
om
e
(F
ig
ur
e
8
,
p.
9
7
8
).
6
p.
9
7
8
.
7
Si
x
co
n
ti
n
en
ts
,
4
3
n
at
io
n
al
an
d
et
hn
ic
gr
ou
ps
in
cl
ud
in
g
in
di
vi
du
al
s
of
Ca
n
ad
ia
n
,
Eu
ro
pe
an
,
As
ia
n
,
bl
ac
k
So
ut
h
Af
ri
ca
n
,
Ar
ab
an
d
N
at
iv
e
Am
er
ic
an
de
sc
en
t.
8
Sh
e
w
as
a
5
7
-y
ea
r-
ol
d
co
n
tr
ol
su
bj
ec
t,
w
it
h
n
o
fa
m
ily
hi
st
or
y
of
H
D
in
>
3
ge
n
er
at
io
n
s,
an
d
un
ex
pe
ct
ed
ly
w
as
fo
un
d
to
ha
ve
3
9
CA
G
re
pe
at
s.
9
Pr
es
um
e
so
m
e
in
di
vi
du
al
s
w
er
e
in
cl
ud
ed
in
ab
ov
e
Ve
n
ez
ue
la
st
ud
ie
s.
1
0
M
em
be
rs
of
Ve
n
ez
ue
la
n
ki
n
dr
ed
s
m
an
ife
st
st
at
is
ti
ca
lly
si
gn
ifi
ca
n
t
ea
rl
ie
r
ag
es
of
H
D
on
se
t
in
co
m
pa
ri
so
n
to
Am
er
ic
an
s
an
d
Ca
n
ad
ia
n
s
(p
.3
5
0
2
).
O
fn
ot
e,
ag
e
of
on
se
t
w
as
la
te
r
w
he
n
on
e
H
TT
al
le
le
in
th
e
co
m
po
un
d
he
te
ro
zy
go
te
s
ha
d
3
5
–
3
9
CA
G
re
pe
at
s.
1
1
Fi
gu
re
1
C,
p.
6
9
1
.
1
2
As
ym
pt
om
at
ic
so
n
w
as
pr
es
ym
pt
om
at
ic
po
si
ti
ve
fo
r
H
D
(1
8
/4
4
CA
G
re
pe
at
s)
.
D
ec
ea
se
d
br
ot
he
r
(4
3
)
ha
d
H
D
on
se
t
la
te
2
0
s.
As
ym
pt
om
at
ic
si
st
er
ha
d
po
si
ti
ve
pr
es
ym
pt
om
at
ic
ge
n
et
ic
te
st
re
su
lt
s
fo
r
H
D
by
re
po
rt
(r
es
ul
ts
un
av
ai
la
bl
e)
.
1156 AMERICAN JOURNAL OF MEDICAL GENETICS PART Athe CAG region alone yielded 42 and 44 repeats. No normal alleles
were seen. A second blood sample was obtained from the patient,
which confirmed these results. As two different allele sizes were
observed, a regional deletion or allele drop-out was unlikely. A
combination of allele drop-out and somaticmosaicismof the single
paternal allele remained a possibility. The CAG studies performed
on the father’s brain tissue yielded 21 and 42 repeats. The patient’s
asymptomatic son had presymptomatic genetic testing and had 18
and 44 CAG repeats; this sample was run concurrently with the
mother’s sample. Therefore, analysis of samples from the patient’s
father and son further confirmed the presence of two allele sizes of
42 and 44 repeats.
When testing for UPD in the patient, a non-paternal (presum-
ablymaternal) allelewas noted for five chromosome4markers used
including D4S127, which is located less than 40 kb telomeric to the
first exon of the HD gene, and D4S412. The D4S412 marker was
informative on the centromeric side and is located approximately
100 kb from the centromeric side of the HD gene. Thus, segmental
UPD was essentially ruled out.DISCUSSION
This is the first reported patientwith biallelicHTTmutationswhere
UPD was excluded. The patient had two HTT alleles in the full
mutation range and one of the higher combinations of CAG repeat
numbers (42/44) reported to date (Table I). Only one parent had
diagnosedHDand thepatient’s parentswerenot related anddidnot
come from a small community.
Given that only the patient’s father was known to be affected
with HD and the rarity of biallelic mutations for this condition, it
was important to confirm this finding and determine etiology.
Uniparental disomywas regarded as anunlikely cause because it has
not been documented for HD and all but one patient [Elli et al.,
2012] with reported UPD(4) to date have been maternal in origin
[Kuchinka et al., 2001; Spena et al., 2004; Middleton et al., 2006;
Cottrell et al., 2012; Ding et al., 2012]. We excluded full and
segmental paternal UPD. Non-maternity is quite rare and there
was no reason to consider it in this family. We believe that the
patient’s mother either had (1) a reduced penetrance allele that
expanded into the full mutation range during transmission to the
patient (a rare event) or (2) an unknown full HTT mutation and
died before symptom onset (unlikely given no family history of
HD and lack of symptoms at age 59).
Unaffected Parent Could Have a Reduced
Penetrance or Intermediate Allele
When a patient with HD and biallelicHTTmutations has just one
affected parent, the unaffected parent with no family history of
HD could have a reduced penetrance or an intermediate HTT
allele. This HTT allele could be stably transmitted, contract
(less common) or expand, even into the full mutation range. In
the general population, approximately 1–6% of individuals have
an intermediate allele and approximtely1–3% have a reduced
penetrance allele [Huntington’s Disease Collaborative Research
Group, 1993; Kremer et al., 1994; Goldberg et al., 1995; Raskin
et al., 2000; Maat-Kievit et al., 2001a, b; Tassiker et al., 2006;
FIG. 1. Pedigree. The known CAG repeat numbers for each HTT allele are in parentheses.
UHLMANN ET AL. 1157Sequeiros et al., 2010; Squitieri and Jankovic, 2012; Semaka et al.,
2013b; Semaka and Hayden, 2014].
In our literature review, we noted a number of patients with HD
and biallelic mutations with just one affected parent and most of
these patients had an intermediate or reduced penetrance allele
(Table I). There were three reported patients with bothHTT alleles
in the fullmutation range and just one parent (mother) affected: 40/
53 repeats [Sanchez et al., 1996], 42/44 and 40/44 repeats [Squitieri
et al., 2003a]. Of note, one of Squitieri et al.’s patients had the
identical number of CAG repeats as the patient reported here, but a
later age of onset (57).
We think it is unlikely that the present patient’s mother had an
intermediate HTT allele because except for one reported patient
[Semaka et al., 2015], maternal expansion of an intermediate allele
into a full HD mutation has not been reported [Goldberg et al.,
1993; Kremer et al., 1995; Maat-Kievit et al., 2001a; Semaka et al.,
2006, 2010; Brocklebank et al., 2009; Semaka and Hayden, 2014].
Although rare, maternal expansions of reduced penetrance HTT
alleles into the full mutation range have been reported [Sanchez
et al., 1997; Laccone and Christian, 2000; Brocklebank et al., 2009;
Aziz et al., 2011] and this may have occurred with the patient
reported here.Higher Prevalence of an HTT Allele 40 repeats
in Biallelic HD and Age of Onset
In our review of the literature (Table I), we made the novel
observation that most patients with HD and biallelic mutations
(reported as homozygous HD) did not have two full mutations.
Most patients had one HTT allele in the reduced penetrance or
intermediate ranges or at 40 CAG repeats, the lower limit of the full
mutation range. Excluding the Venezuela cases (where overall age
of onset is thought to be earlier in this extended pedigree), there
were 12 patients with onset at age 49 or older and 11 had an allele
with 40 or less repeats (the exception is Squitieri et al., [2003a]
patient with 42/44 repeats). Five patients had onset at ages 22–33
and all had an allele >45 repeats. For the three patients with both
alleles >40, age of onset ranged from 33 to 57.
It was suggested in the literature that patients with biallelic
mutations have a similar age of onset as do heterozygotes [Young
et al., 1986; Wexler et al., 1987; Myers et al., 1989; Kremer et al.,
1994; Durr et al., 1999; Laccone et al., 1999; Alonso et al., 2002;
Costa et al., 2003]. Lee et al. [2012] concluded that the presence of a
second HTT allele did not significantly impact the age of onset of
motor symptoms of HD, which they found was primarily deter-
1158 AMERICAN JOURNAL OF MEDICAL GENETICS PART Amined by the larger expanded allele. In our compilation of reports
(Table I), patients who had biallelic mutations with an expanded
HTT allele 40 CAG repeats generally had symptoms starting in
their 50s,which is later than themean age ofHDonset [Warby et al.,
1998]. This interpretation is based on a limited number of patients
and therefore should be corroborated with a larger number of
patients with biallelic mutations. While a later age of HD onset has
also been seen in individuals with large normal alleles [Snell et al.,
1993; Djousse et al., 2003; Aziz et al., 2009], our interpretation is
problematic because it would imply that patients with no normal
HTT alleles may have a later age of onset than those with just one
expanded allele; further investigation is warranted.
Terminology
In our literature review, “homozygotes” was the term universally
used to describe individuals with two expanded HTT alleles. We
propose that “biallelic HD/mutations/expansions” (preferred) or
“compound heterozygotes” rather than “homozygotes” are more
accurate terms to describe individuals with two expanded HTT
alleles not identical by descent. The terms “biallelic mutations” and
“compound heterozygosity” are used with other autosomal domi-
nant conditions including familial hypercholesterolemia [Yao et al.,
2012; Youngblom and Knowles, 2014] facioscapulohumeral mus-
cular dystrophy [Scionti et al., 2012] and hereditary colorectal
cancer [Lindor, 2009].
Genetic Counseling
Biallelic HD has significant risk implications for offspring (obligate
heterozygotes for an expanded HTT allele), the patient’s siblings
(75% risk to have one or both expandedHTT alleles), the patient’s
parents (obligate heterozygotes) and other relatives. There are
challenging counseling and ethical issues to consider when biallelic
HD is discovered [Alonso et al., 2002; Costa et al., 2003; Squitieri
et al., 2003b]. The ages of children, timing of disclosure, “do no
harm” and the preservation of the “right not to know” are signifi-
cant considerations.
When a patient with biallelic HD is identified with just one
affected parent (and parentage is certain) and the other parent has
no family history of HD, a likely explanation is that the unaffected
parent has an intermediate or reduced penetrance HTT allele that
has either been stably transmitted or expanded. If the patient with
biallelic HD has two full mutations and the mother is unaffected, it
is highly likely that she has a reduced penetrance allele. An unaf-
fected father could have a reduced penetrance (more likely) or an
intermediate allele that expands upon transmission.
Although the number of reports is limited, we noted in our
review that most patients with biallelic HD do not have two full
mutations and those with one expanded HTT allele of 40 CAG
repeats generally had onset in their 50s. This could have significant
implications for recurrence risks. Analyses of more individuals
with biallelic HD and comparison of both of their HTT alleles
to the known mean ages of onset for the CAG repeats will be
important for both assessing if patients with one or two HTT
mutations have differential ages of onset and providing accurate
onset information.ACKNOWLEDGMENT
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